Search Results - "TROUBOUL, Fanny"

Abstract GS3-05: Fulvestrant-palbociclib vs continuing aromatase inhibitor-palbociclib upon detection of circulating ESR1 mutation in HR+ HER2- metastatic breast cancer patients: Results of PADA-1, a UCBG-GINECO randomized phase 3 trial by Bidard, François-Clément, Hardy-Bessard, Anne-Claire, Bachelot, Thomas, Pierga, Jean-Yves, Canon, Jean-Luc, Clatot, Florian, Andre, Fabrice, De La Motte Rouge, Thibault, Pistilli, Barbara, Dalenc, Florence, Dohollou, Nadine, Arsene, Olivier, Petit, Thierry, Riedl, Cécilia, Morvan, François, Marti, Adina, Lachaier, Emma, Achille, Mihaela, Gozy, Michel, Escande, Anne, Mille, Dominique, Trouboul, Fanny, Arnould, Laurent, Bieche, Ivan, Pradines, Anne, Lemonnier, Jerome, Berger, Frederique, Delaloge, Suzette

“…Abstract Background: ESR1 mutations are known drivers of resistance to first line aromatase inhibitors (AI)-based therapy in hormone receptor-positive (HR+)…”
Get full text

Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial by Bidard, François-Clément, Hardy-Bessard, Anne-Claire, Dalenc, Florence, Bachelot, Thomas, Pierga, Jean-Yves, de la Motte Rouge, Thibault, Sabatier, Renaud, Dubot, Coraline, Ferrero, Jean Marc, Ladoire, Sylvain, Levy, Christelle, Mouret-Reynier, Marie-Ange, Lortholary, Alain, Grenier, Julien, Chakiba, Camille, Stefani, Laetitia, Plaza, Jérôme Edouard, Clatot, Florian, Teixeira, Luis, D'Hondt, Véronique, Vegas, Hélène, Derbel, Olfa, Garnier-Tixidre, Claire, Canon, Jean-Luc, Pistilli, Barbara, André, Fabrice, Bièche, Ivan, Callens, Céline, Lemonnier, Jérôme, Delaloge, Suzette, PISTILLI, Barbara, DALENC, Florence, BACHELOT, Thomas, SABATIER, Renaud, DUBOT, Coraline, FRENEL, Jean-Sébastien, FERRERO, Jean-Marc, LADOIRE, Sylvain, LEVY, Christelle, MOURET-REYNIER, Marie-Ange, HARDY-BESSARD, Anne-Claire, LORTHOLARY, Alain, GRENIER, Julien, CHAKIBA, Camille, STEFANI, Laetitia, SOULIE, Patrick, PLAZA, Jérôme Edouard, CLATOT, Florian, TEIXEIRA, Luis, D'HONDT, Véronique, VEGAS, Hélène, DERBEL, Olfa, GARNIER TIXIDRE, Claire, CHENEAU, Caroline, PAITEL, Jean-François, BERNARD-MARTY, Chantal, SPAETH, Dominique, MOULLET, Isabelle, DEIANA, Laura, GREILSAMER, Charlotte, VENAT-BOUVET, Laurence, DELECROIX, Valérie, MELIS, Adrien, ORFEUVRE, Hubert, NGUYEN, Suzanne, LEGOUFFE, Eric, ZANNETTI, Alain, LE SCODAN, Romuald, DOHOLLOU, Nadine, DALIVOUST, Philippe, ARSENE, Olivier, MARQUES, Nathalie, PETIT, Thierry, MOLLON, Delphine, DAUBA, Jérôme, BONNIN, Nathalie, GARDNER, Miriam, MARTI, Adina, LEVACHE, Charles-Briac, LACHAIER, Emma, ACHILLE, Mihaela, VALMAR, Christophe, BOUAITA, Ryan, MEDIONI, Jacques, FOA, Cyril, DEL PIANO, Francesco, GOZY, Michel, ESCANDE, Anne, LEDUC, Nicolas, LUCAS, Brigitte, AMMARGUELLAT, Hanifa, NAJEM, Abeer, TROUBOUL, Fanny, DESCLOS, Hervé, MAYEUR, Didier, LORCHEL, Fabrice, BOUDRANT, Axelle, GISSEROT, Olivier, ALLEAUME, Corinne, DE GRAMONT, Aimery

“…In advanced oestrogen receptor-positive, HER2-negative breast cancer, acquired resistance to aromatase inhibitors frequently stems from ESR1-mutated subclones,…”
Get full text

Abstract P1-18-16: First line aromatase inhibitor (AI) + palbociclib with randomized switch to fulvestrant + palbociclib upon detection of circulating ESR1 mutation in HR+ HER2- metastatic breast cancer patients: Global safety results of PADA-1, a UCBG-GINECO phase III trial by Delaloge, Suzette, Hardy-Bessard, Anne-Claire, Bachelot, Thomas, Pierga, Jean-Yves, Canon, Jean-Luc, Clatot, Florian, André, Fabrice, Rouge, Thibault De La Motte, Pistilli, Barbara, Dalenc, Florence, Dohollou, Nadine, Arsene, Olivier, Petit, Thierry, Riedl, Cecilia, Morvan, François, Marti, Adina, Lachaier, Emma, Achille, Mihaela, Gozy, Michel, Escande, Anne, Mille, Dominique, Trouboul, Fanny, Marques, Sandrine, Lemonnier, Jerome, Berger, Frederique, Bidard, François-Clément

“…Abstract Background: Aromatase inhibitors (AI) in combination with a CDK 4/6 inhibitor have been established as the standard first line treatment of non…”
Get full text

Trastuzumab induced cardiotoxicity in HER2-positive metastatic esogastric cancers by Martin-Babau, Jerome, Eusen, Yves, Verveur, Cedric, Trouboul, Fanny, Cheneau, Caroline, Jestin Le Tallec, Veronique, Simon, Helene, Metges, Jean-Philippe

“…Abstract only 152 Background: Trastuzumab is widely used in Her2 positive metastatic esophageal and gastric cancers along with chemotherapy. Cardiotoxicity of…”
Get full text